Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alice Tsang Shaw, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Alice Shaw and Ibiayi Dagogo-Jack.
Connection Strength

10.948
  1. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clin Cancer Res. 2019 11 15; 25(22):6662-6670.
    View in: PubMed
    Score: 0.886
  2. BRAF Mutation Class and Clinical Outcomes-Response. Clin Cancer Res. 2019 05 15; 25(10):3189.
    View in: PubMed
    Score: 0.874
  3. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol. 2019 05; 14(5):816-824.
    View in: PubMed
    Score: 0.854
  4. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 02; 15(2):81-94.
    View in: PubMed
    Score: 0.787
  5. Expanding the Roster of ROS1 Inhibitors. J Clin Oncol. 2017 08 10; 35(23):2595-2597.
    View in: PubMed
    Score: 0.761
  6. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 10; 12(10):e155-e157.
    View in: PubMed
    Score: 0.760
  7. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016 09; 27 Suppl 3:iii42-iii50.
    View in: PubMed
    Score: 0.725
  8. Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. J Thorac Oncol. 2016 09; 11(9):1522-8.
    View in: PubMed
    Score: 0.713
  9. Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics? Oncologist. 2016 06; 21(6):662-3.
    View in: PubMed
    Score: 0.712
  10. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 Feb 03.
    View in: PubMed
    Score: 0.246
  11. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21.
    View in: PubMed
    Score: 0.238
  12. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2535-2545.
    View in: PubMed
    Score: 0.230
  13. Clinicopathologic Characteristics of BRG1-Deficient NSCLC. J Thorac Oncol. 2020 05; 15(5):766-776.
    View in: PubMed
    Score: 0.229
  14. Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2020 02; 15(2):258-265.
    View in: PubMed
    Score: 0.225
  15. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. J Thorac Oncol. 2019 05; 14(5):835-843.
    View in: PubMed
    Score: 0.214
  16. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. J Thorac Oncol. 2018 11; 13(11):e226-e227.
    View in: PubMed
    Score: 0.210
  17. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165.
    View in: PubMed
    Score: 0.209
  18. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.207
  19. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.203
  20. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.200
  21. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.194
  22. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. J Immunother. 2017 04; 40(3):108-113.
    View in: PubMed
    Score: 0.189
  23. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer. Clin Pharmacol Ther. 2017 May; 101(5):625-633.
    View in: PubMed
    Score: 0.188
  24. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017; 37:619-629.
    View in: PubMed
    Score: 0.185
  25. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.180
  26. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 Mar 08.
    View in: PubMed
    Score: 0.062
  27. Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer. Cancer. 2020 Oct 15; 126(20):4473-4484.
    View in: PubMed
    Score: 0.059
  28. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. J Thorac Oncol. 2020 09; 15(9):1497-1506.
    View in: PubMed
    Score: 0.058
  29. Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. Lung Cancer. 2019 03; 129:80-84.
    View in: PubMed
    Score: 0.053
  30. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):255-264.
    View in: PubMed
    Score: 0.053
  31. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018 10; 13(10):1530-1538.
    View in: PubMed
    Score: 0.051
  32. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 2018 08; 122:67-71.
    View in: PubMed
    Score: 0.051
  33. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018 05; 24(4):512-517.
    View in: PubMed
    Score: 0.050
  34. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 04 20; 36(12):1199-1206.
    View in: PubMed
    Score: 0.050
  35. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. J Thorac Oncol. 2016 07; 11(7):e83-5.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.